Blinktbi, Inc, a medical device company, announces the appointment of Jeffrey Riley as Chief Executive Officer and to the company's Board of Directors. The developer of the blink reflex technology – EyeStat, which tests and identifies a variety of neurological states and conditions is looking forward to expansion with the new hiring. The company’s founding CEO, Dr. Doug Carnes will remain as Chief Operating Officer and continue to serve as a Member of the Board of Directors.

Jeffrey has more than 25 years of experience in the biotechnology and pharmaceutical industries. His healthcare and biotechnology experience spans across leadership positions with SmithKline Beecham, Pfizer, Quest Diagnostics, Xenome, Ontogen and most recently as CEO, President and Director of Synthetic Biologics. The founder and partner of 526 Ventures, he is also a director board member for Chinook Medical Gear, Inc. and Gain Therapeutics.  

In a statement, Dr. Doug Carnes, blinktbi's co-founder and former Chief Executive Officer, says “As we align our proprietary EyeStat technology platform with an expanded clinical focus, Jeff's proven leadership, focused vision, and ability to bring the right people together make him the ideal person to lead our company during this transition.” He adds, “Jeff's considerable clinical and corporate development experience will be instrumental in shaping blinktbi for its next chapter of product innovation and growth. I'm excited to be staying on as Chief Operations Officer and look forward to working with Jeff and the blinktbi team to advance our shared vision for the future of our company.”

EyeStat, blinktbi's flagship platform, captures a subject's baseline blink reflex and subsequent scans can be used, if warranted, by clinicians to evaluate and assess for abnormalities of the blink reflex. The company had received FDA approval for the product in January.